The effects of trimethadione (TMO) and its metabolite, dimethadione
Introduction TMO is extensively metabolized to DMO by cytochrome P-450 dependent monooxygenase and is almost completely absorbed from the gastrointestinal tract when given orally. Neither TMO nor DMO is bound to plasma protein. From these properties we used the serum concentration ratio, DMO/TMO, as an index of hepatic drug oxidizing capacity in human1-3). Nevertheless, we do not know the isozyme of P-450 that is responsible for demethylation of TMO in human.
Debrisoquine 4-hydroxylase is a well-known isozyme of P-450 in humans. About 10% of the Caucasian population has an inherited deficiency of 4-hydroxylation of debrisoquine as the debrisoquine polymorphism4,5) and these poor metabolizers are at high risk to develop adverse responses to such drugs as f3-blocker, antiarrhythmics, antidepressants, hallucinogenes, opioids and others6). To avoid the clinical risk of these drugs, the urinary excretion ratio of 4-hydroxydebrisoquine to debrisoquine after oral administration of debrisoquine has been used to determine debrisoquine polymorphism in humans5). We have previously studied the activities of both TMO N-demethylase and debrisoquine 4-hydroxylase in vivo in humans after simultaneous oral administration of TMO and debrisoquine.
In the present study we investigated the possibility that TMO or DMO affects the activity of debrisoquine 4-hydroxylase in human liver in vitro, since, if TMO can be catalyzed to DMO by this P-450 isozyme, or if TMO or DMO can bind to an active site of debrisoquine 4-hydroxylase, its activity might be inhibited by addition of TMO or DMO in vitro. Additionally, the activity of TMO demethylase in human liver in vitro has not yet been determined. 19:721-729 (1985) 10) Boobis AR, Murray S, Kahn GC, Robertz GM and Davies DS: Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol, 23:474-481 (1983) 11) Tanaka E, Kinoshita H, Yoshida T and Kuroiwa Y: Studies on the trimethadione metabolism as a tool for the assessment of drug-metabolizing capacity using plasma and urine of rats pretreated with phenobarbital and 3-methylcholanthren. I Pharm Dyn, 5: 162-171 (1982) 12) Nebert DW and Gonzalez FJ: P-450: structure, evolution, and regulation. Annu Rev Biochem, 56: 945-993 (1987) 13) Zackai EH, Mellman WJ and Meiderer B: The fetal trimethadione syndrome. J Pediatr, 87:280-284 (1985) 
